FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Prescribed drugs, Inc. (NASDAQ: MIRM) at this time introduced that it’ll host an investor name on Monday, June 17 at 8:30 a.m. ET to share interim evaluation outcomes from the Volixibat VANTAGE Section 2b examine in major biliary cholangitis (PBC) and the Volixibat VISTAS Section 2b examine in major sclerosing cholangitis (PSC).
Convention name particulars:
Monday June 17, 2024
8:30 a.m. ET / 5:30 a.m. PT
Dial-in:
U.S./Toll-Free: +1 833 470 1428
Worldwide: +1 404 975 4839
Passcode: 205511
You might also entry the decision by way of webcast by visiting the Occasions & Shows part on Mirum’s web site. A replay of this webcast shall be obtainable for 30 days.
About Mirum Prescribed drugs (NASDAQ:), Inc.
Mirum Prescribed drugs, Inc. is a biopharmaceutical firm devoted to remodeling the remedy of uncommon ailments affecting kids and adults. Mirum has three permitted drugs: LIVMARLI ® (maralixibat) oral resolution, CHOLBAM ® (cholic acid) capsules, and CHENODAL ® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is permitted for the remedy of two uncommon liver ailments affecting kids and adults. It’s permitted for the remedy of cholestatic pruritus in sufferers with Alagille syndrome within the U.S. (three months and older), in Europe (two months and older), and in different areas globally. It is usually permitted within the U.S. in cholestatic pruritus in PFIC sufferers 5 years of age and older. LIVMARLI has acquired constructive opinion by CHMP in Europe for the remedy of PFIC in sufferers three months of age and older. A call by the European Fee is predicted by the third quarter of 2024. CHOLBAM is FDA-approved for the remedy of bile acid synthesis problems attributable to single enzyme deficiencies and adjunctive remedy of peroxisomal problems in sufferers who present indicators or signs or liver illness. CHENODAL has acquired medical necessity recognition by the FDA to deal with sufferers with cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline contains two investigational therapies for debilitating liver ailments. Volixibat, an IBAT inhibitor, is being evaluated in two probably registrational research together with the Section 2b VISTAS examine for major sclerosing cholangitis and Section 2b VANTAGE examine for major biliary cholangitis. Lastly, CHENODAL has been evaluated in a Section 3 scientific examine, RESTORE, to deal with sufferers with CTX, with constructive topline outcomes reported in 2023.
To study extra about Mirum, go to mirumpharma.com and comply with Mirum on Fb (NASDAQ:), LinkedIn, Instagram and Twitter (X).
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240616032628/en/
Buyers:
Andrew McKibben
ir@mirumpharma.com
Media:
Erin Murphy
media@mirumpharma.com
Supply: Mirum Prescribed drugs, Inc.